These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 25100872)

  • 1. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
    Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
    Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib.
    Cardona AF; Ruiz-Patiño A; Zatarain-Barrón ZL; Hakim F; Jiménez E; Mejía JA; Ramón JF; Useche N; Bermúdez S; Pineda D; Cifuentes H; Rojas L; Ricaurte L; Pino LE; Balaña C; Arrieta O
    PLoS One; 2019; 14(6):e0217340. PubMed ID: 31220093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
    Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
    Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib for atypical and anaplastic meningioma.
    Rahman A
    Lancet Oncol; 2014 Sep; 15(10):e424. PubMed ID: 25328951
    [No Abstract]   [Full Text] [Related]  

  • 7. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma.
    Chamberlain MC
    J Neurooncol; 2012 Apr; 107(2):315-21. PubMed ID: 22127733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
    Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
    Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.
    Wang Y; Li W; Jing N; Meng X; Zhou S; Zhu Y; Xu J; Tao R
    Cancer Biol Ther; 2020 Jul; 21(7):583-589. PubMed ID: 32212907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical and anaplastic meningiomas treated with bevacizumab.
    Nayak L; Iwamoto FM; Rudnick JD; Norden AD; Lee EQ; Drappatz J; Omuro A; Kaley TJ
    J Neurooncol; 2012 Aug; 109(1):187-93. PubMed ID: 22544653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
    Choong NW; Kozloff M; Taber D; Hu HS; Wade J; Ivy P; Karrison TG; Dekker A; Vokes EE; Cohen EE
    Invest New Drugs; 2010 Oct; 28(5):677-83. PubMed ID: 19649772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
    Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
    Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
    Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
    Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report.
    Raheja A; Colman H; Palmer CA; Couldwell WT
    J Neurosurg; 2017 Nov; 127(5):965-970. PubMed ID: 27935362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
    Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
    J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics.
    Yoshikawa A; Nakada M; Ohtsuki S; Hayashi Y; Obuchi W; Sato Y; Ikeda C; Watanabe T; Kawahara Y; Hasegawa T; Sabit H; Kita D; Hayashi Y; Nakanuma Y; Terasaki T; Hamada JI
    Neuropathol Appl Neurobiol; 2012 Feb; 38(1):105-10. PubMed ID: 21696419
    [No Abstract]   [Full Text] [Related]  

  • 17. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
    Hutterer M; Nowosielski M; Haybaeck J; Embacher S; Stockhammer F; Gotwald T; Holzner B; Capper D; Preusser M; Marosi C; Oberndorfer S; Moik M; Buchroithner J; Seiz M; Tuettenberg J; Herrlinger U; Wick A; Vajkoczy P; Stockhammer G
    Neuro Oncol; 2014 Jan; 16(1):92-102. PubMed ID: 24311637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD
    J Clin Oncol; 2008 Apr; 26(11):1810-6. PubMed ID: 18347007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
    Bang YJ; Kang YK; Kang WK; Boku N; Chung HC; Chen JS; Doi T; Sun Y; Shen L; Qin S; Ng WT; Tursi JM; Lechuga MJ; Lu DR; Ruiz-Garcia A; Sobrero A
    Invest New Drugs; 2011 Dec; 29(6):1449-58. PubMed ID: 20461441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
    Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
    Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.